GC
Therapeutic Areas
Foghorn Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FHD-286 | Relapsed/Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) | Phase 1 |
| FHD-609 | Synovial Sarcoma and SMARCB1-deleted Tumors | Phase 1 |
| FVH-286 | Ophthalmology (e.g., Geographic Atrophy) | Preclinical |
| BRM Selective Program | Undisclosed Oncology | Discovery |
Leadership Team at Foghorn Therapeutics
AG
Adrian Gottschalk, J.D.
President and Chief Executive Officer
CK
Cigall Kadoch, Ph.D.
Co-Founder, Scientific Advisory Board Chair, and Director
SA
Samuel Agresta, M.D., M.P.H.
Chief Medical Officer
ML
Michael LaCascia, J.D.
Chief Business Officer
AB
Allison Burr, J.D.
Executive Vice President, Corporate Affairs & General Counsel
JM
Joel Marcus
Executive Chairman and Chairman of the Board
AS
Alfred Scheidegger, Ph.D.
Chief Scientific Officer
SB
Steven Bellon, Ph.D.
Chief Technology Officer
KS
Katherine S. Bowdish, Ph.D.
Director
WK
William K. Heiden
Director